REG - Haleon PLC - Transactions in Own Shares

HALEONAnnouncement

27/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260427:nRSa9123Ba&default-theme=true

RNS Number : 9123B  Haleon PLC  27 April 2026

 

Haleon plc: Aggregated information - transactions in own shares

 

27 April 2026: Haleon plc (the "Company" or "Haleon") today announces the
purchase of 8,444,107 ordinary shares of £0.01 each in the Company (the
"Shares") for cancellation under its share buyback programme announced on 12
March 2026.

 

                                                    London Stock Exchange  CBOE (UK)/BXE  CBOE (UK)/CXE  Aquis
 Date of purchase:                                  20 April 2026
 Number of Shares purchased:                        821,869                367,453        507,955        -
 Highest price paid per Share (p):                  357.1000               357.0000       357.0000       -
 Lowest price paid per Share (p):                   352.7000               352.7000       352.7000       -
 Volume weighted average price paid per Share (p):  355.6853               355.6923       355.7028       -
 Date of purchase:                                  21 April 2026
 Number of Shares purchased:                        1,166,530              588,755        744,522        -
 Highest price paid per Share (p):                  356.8000               356.8000       356.8000       -
 Lowest price paid per Share (p):                   351.3000               351.3000       351.3000       -
 Volume weighted average price paid per Share (p):  353.4925               353.2870       353.4540       -
 Date of purchase:                                  22 April 2026
 Number of Shares purchased:                        1,704,866              979,361        797,024        -
 Highest price paid per Share (p):                  347.3000               347.3000       347.3000       -
 Lowest price paid per Share (p):                   342.7000               342.7000       342.7000       -
 Volume weighted average price paid per Share (p):  345.6215               345.6369       345.6370       -
 Date of purchase:                                  23 April 2026
 Number of Shares purchased:                        213,670                112,840        164,286        -
 Highest price paid per Share (p):                  351.4000               351.3000       351.3000       -
 Lowest price paid per Share (p):                   344.8000               344.8000       344.3000       -
 Volume weighted average price paid per Share (p):  348.5780               348.5651       348.1893       -
 Date of purchase:                                  24 April 2026
 Number of Shares purchased:                        111,010                73,582         90,384         -
 Highest price paid per Share (p):                  356.1000               356.1000       355.4000       -
 Lowest price paid per Share (p):                   350.5000               350.4000       350.4000       -
 Volume weighted average price paid per Share (p):  352.1838               352.3097       352.1778       -

 

Following the settlement of the above, the Company's registered share capital
is 8,902,639,582 ordinary shares of £0.01 each, of which 12,281,053 are
held as treasury shares. Therefore, the number of ordinary shares with voting
rights is 8,890,358,529 and this figure may be used by shareholders to
determine if they are required to notify their interest, or a change to their
interest, in Haleon under the FCA's Disclosure Guidance and Transparency
Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it
applies in the UK (the Market Abuse Regulation), a full breakdown of the
individual trades is available at the link below:

 

http://www.rns-pdf.londonstockexchange.com/rns/9123B_1-2026-4-24.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/9123B_1-2026-4-24.pdf)

 

This announcement does not constitute, or form part of, an offer or any
solicitation of an offer for securities in any jurisdiction.

 

This announcement and individual trade breakdown will also be available on the
Company's website at: www.haleon.com/investors
(http://www.haleon.com/investors) .

 

 Enquiries

 Investors                                                                       Media

 Jo Russell                              +44 7787 392441                         Zoë Bird                             +44 7736 746167
 Rakesh Patel                            +44 7552 484646                         Victoria Durman                      +44 7894 505730
 Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com)     Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better
everyday health. Our people, our brands, our research, our investment and our
innovation are aimed at improving the everyday health of consumers. Our
product portfolio spans six major categories - Oral Health, Vitamins, Minerals
and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and
Therapeutic Skin Health and Other. Our superior brands - such as Advil,
Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and
Voltaren - are trusted by more than one billion consumers and are recommended
by health professionals around the world.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSBLGDSRUDDGLS



            Copyright 2019 Regulatory News Service, all rights reserved